BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Depetter Y, Geurs S, De Vreese R, Goethals S, Vandoorn E, Laevens A, Steenbrugge J, Meyer E, de Tullio P, Bracke M, D'hooghe M, De Wever O. Selective pharmacological inhibitors of HDAC6 reveal biochemical activity but functional tolerance in cancer models: Activity of HDAC6 inhibitors in cancer models. Int J Cancer 2019;145:735-47. [DOI: 10.1002/ijc.32169] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Losson H, Gajulapalli SR, Lernoux M, Lee JY, Mazumder A, Gérard D, Seidel C, Hahn H, Christov C, Dicato M, Kirsch G, Han BW, Schnekenburger M, Diederich M. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia. Pharmacol Res 2020;160:105058. [PMID: 32619722 DOI: 10.1016/j.phrs.2020.105058] [Reference Citation Analysis]
2 Saraswati AP, Relitti N, Brindisi M, Osko JD, Chemi G, Federico S, Grillo A, Brogi S, McCabe NH, Turkington RC, Ibrahim O, O'Sullivan J, Lamponi S, Ghanim M, Kelly VP, Zisterer D, Amet R, Hannon Barroeta P, Vanni F, Ulivieri C, Herp D, Sarno F, Di Costanzo A, Saccoccia F, Ruberti G, Jung M, Altucci L, Gemma S, Butini S, Christianson DW, Campiani G. Spiroindoline-Capped Selective HDAC6 Inhibitors: Design, Synthesis, Structural Analysis, and Biological Evaluation. ACS Med Chem Lett 2020;11:2268-76. [PMID: 33214839 DOI: 10.1021/acsmedchemlett.0c00395] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Li Y, Quan J, Song H, Li D, Ma E, Wang Y, Ma C. Novel pyrrolo[2,1-c][1,4]benzodiazepine-3,11-dione (PBD) derivatives as selective HDAC6 inhibitors to suppress tumor metastasis and invasion in vitro and in vivo. Bioorg Chem 2021;114:105081. [PMID: 34153811 DOI: 10.1016/j.bioorg.2021.105081] [Reference Citation Analysis]
4 Toro TB, Watt TJ. Critical review of non-histone human substrates of metal-dependent lysine deacetylases. FASEB J 2020;34:13140-55. [PMID: 32862458 DOI: 10.1096/fj.202001301RR] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Beyer M, Romanski A, Mustafa AM, Pons M, Büchler I, Vogel A, Pautz A, Sellmer A, Schneider G, Bug G, Krämer OH. HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of β-catenin, MYC, and WT1. Cancers (Basel) 2019;11:E1436. [PMID: 31561534 DOI: 10.3390/cancers11101436] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
6 Dawood M, Fleischer E, Klinger A, Bringmann G, Shan L, Efferth T. Inhibition of cell migration and induction of apoptosis by a novel class II histone deacetylase inhibitor, MCC2344. Pharmacol Res 2020;160:105076. [PMID: 32659428 DOI: 10.1016/j.phrs.2020.105076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
7 Losson H, Schnekenburger M, Dicato M, Diederich M. HDAC6-an Emerging Target Against Chronic Myeloid Leukemia? Cancers (Basel) 2020;12:E318. [PMID: 32013157 DOI: 10.3390/cancers12020318] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
8 Auzmendi-Iriarte J, Saenz-Antoñanzas A, Mikelez-Alonso I, Carrasco-Garcia E, Tellaetxe-Abete M, Lawrie CH, Sampron N, Cortajarena AL, Matheu A. Characterization of a new small-molecule inhibitor of HDAC6 in glioblastoma. Cell Death Dis 2020;11:417. [PMID: 32488056 DOI: 10.1038/s41419-020-2586-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Rodrigues DA, Guerra FS, Sagrillo FS, de Sena M Pinheiro P, Alves MA, Thota S, Chaves LS, Sant'Anna CMR, Fernandes PD, Fraga CAM. Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors. ChemMedChem 2020;15:539-51. [PMID: 32022441 DOI: 10.1002/cmdc.201900716] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
10 Sundaramurthi H, García-mulero S, Tonelotto V, Slater K, Marcone S, Piulats JM, Watson RW, Tobin DJ, Jensen LD, Kennedy BN. Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor. Cancers 2022;14:782. [DOI: 10.3390/cancers14030782] [Reference Citation Analysis]
11 Lin A, Giuliano CJ, Palladino A, John KM, Abramowicz C, Yuan ML, Sausville EL, Lukow DA, Liu L, Chait AR, Galluzzo ZC, Tucker C, Sheltzer JM. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci Transl Med 2019;11:eaaw8412. [PMID: 31511426 DOI: 10.1126/scitranslmed.aaw8412] [Cited by in Crossref: 173] [Cited by in F6Publishing: 142] [Article Influence: 86.5] [Reference Citation Analysis]
12 Federico S, Khan T, Fontana A, Brogi S, Benedetti R, Sarno F, Carullo G, Pezzotta A, Saraswati AP, Passaro E, Pozzetti L, Papa A, Relitti N, Gemma S, Butini S, Pistocchi A, Ramunno A, Vincenzi F, Varani K, Tatangelo V, Patrussi L, Baldari CT, Saponara S, Gorelli B, Lamponi S, Valoti M, Saccoccia F, Giannaccari M, Ruberti G, Herp D, Jung M, Altucci L, Campiani G. Azetidin-2-one-based small molecules as dual hHDAC6/HDAC8 inhibitors: Investigation of their mechanism of action and impact of dual inhibition profile on cell viability. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114409] [Reference Citation Analysis]
13 Rodrigues DA, Pinheiro PDSM, Sagrillo FS, Bolognesi ML, Fraga CAM. Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities. Med Res Rev 2020;40:2177-211. [DOI: 10.1002/med.21701] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
14 Ghazy E, Zeyen P, Herp D, Hügle M, Schmidtkunz K, Erdmann F, Robaa D, Schmidt M, Morales ER, Romier C, Günther S, Jung M, Sippl W. Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1. Eur J Med Chem 2020;200:112338. [PMID: 32497960 DOI: 10.1016/j.ejmech.2020.112338] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
15 Pflieger M, Sönnichsen M, Horstick-Muche N, Yang J, Schliehe-Diecks J, Schöler A, Borkhardt A, Hamacher A, Kassack MU, Hansen FK, Bhatia S, Kurz T. Oxa Analogues of Nexturastat A Demonstrate Improved HDAC6 Selectivity and Superior Antileukaemia Activity. ChemMedChem 2021;16:1798-803. [PMID: 33629513 DOI: 10.1002/cmdc.202001011] [Reference Citation Analysis]
16 He X, Li Z, Zhuo XT, Hui Z, Xie T, Ye XY. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019). Recent Pat Anticancer Drug Discov 2020;15:32-48. [PMID: 32065106 DOI: 10.2174/1574892815666200217125419] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Nawar N, Bukhari S, Adile AA, Suk Y, Manaswiyoungkul P, Toutah K, Olaoye OO, Raouf YS, Sedighi A, Garcha HK, Hassan MM, Gwynne W, Israelian J, Radu TB, Geletu M, Abdeldayem A, Gawel JM, Cabral AD, Venugopal C, de Araujo ED, Singh SK, Gunning PT. Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma. J Med Chem 2022. [PMID: 35119267 DOI: 10.1021/acs.jmedchem.1c01585] [Reference Citation Analysis]
18 Milazzo G, Mercatelli D, Di Muzio G, Triboli L, De Rosa P, Perini G, Giorgi FM. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability. Genes (Basel) 2020;11:E556. [PMID: 32429325 DOI: 10.3390/genes11050556] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 19.5] [Reference Citation Analysis]
19 Lin A, Sheltzer JM. Discovering and validating cancer genetic dependencies: approaches and pitfalls. Nat Rev Genet 2020;21:671-82. [DOI: 10.1038/s41576-020-0247-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
20 Reßing N, Sönnichsen M, Osko JD, Schöler A, Schliehe-Diecks J, Skerhut A, Borkhardt A, Hauer J, Kassack MU, Christianson DW, Bhatia S, Hansen FK. Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups. J Med Chem 2020;63:10339-51. [PMID: 32803970 DOI: 10.1021/acs.jmedchem.9b01888] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Morgen M, Steimbach RR, Géraldy M, Hellweg L, Sehr P, Ridinger J, Witt O, Oehme I, Herbst-Gervasoni CJ, Osko JD, Porter NJ, Christianson DW, Gunkel N, Miller AK. Design and Synthesis of Dihydroxamic Acids as HDAC6/8/10 Inhibitors. ChemMedChem 2020;15:1163-74. [PMID: 32348628 DOI: 10.1002/cmdc.202000149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
22 Schlüter A, Aksan B, Fioravanti R, Valente S, Mai A, Mauceri D. Histone Deacetylases Contribute to Excitotoxicity-Triggered Degeneration of Retinal Ganglion Cells In Vivo. Mol Neurobiol 2019;56:8018-34. [PMID: 31161423 DOI: 10.1007/s12035-019-01658-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
23 Ali A, Zhang F, Maguire A, Byrne T, Weiner-Gorzel K, Bridgett S, O'Toole S, O'Leary J, Beggan C, Fitzpatrick P, McCann A, Furlong F. HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells. Cancers (Basel) 2020;12:E3734. [PMID: 33322608 DOI: 10.3390/cancers12123734] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
24 Abdel-Atty MM, Farag NA, Serya RAT, Abouzid KAM, Mowafy S. Molecular design, synthesis and in vitro biological evaluation of thienopyrimidine-hydroxamic acids as chimeric kinase HDAC inhibitors: a challenging approach to combat cancer. J Enzyme Inhib Med Chem 2021;36:1290-312. [PMID: 34187263 DOI: 10.1080/14756366.2021.1933465] [Reference Citation Analysis]
25 Selg C, Schöler A, Schliehe-Diecks J, Hanl M, Sinatra L, Borkhardt A, Sárosi MB, Bhatia S, Hey-Hawkins E, Hansen FK. Borinostats: solid-phase synthesis of carborane-capped histone deacetylase inhibitors with a tailor-made selectivity profile. Chem Sci 2021;12:11873-81. [PMID: 34659728 DOI: 10.1039/d1sc02268g] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Suzdalev KF, Vyalyh JV, Tkachev VV, Lysenko EA, Burov ON, Lisovin AV, Kletskii ME, Kurbatov SV. Lithium-Promoted Cycloaddition of Indole-2,3-dienolates and Carbon Disulfide as a One-Pot Route to Thiopyrano[4,3-b]indole-3(5H)-thiones. J Org Chem 2021;86:11698-707. [PMID: 34338514 DOI: 10.1021/acs.joc.1c01200] [Reference Citation Analysis]
27 Rodrigues DA, Pinheiro PSM, Fraga CAM. Multitarget Inhibition of Histone Deacetylase (HDAC) and Phosphatidylinositol-3-kinase (PI3K): Current and Future Prospects. ChemMedChem 2021;16:448-57. [PMID: 33049098 DOI: 10.1002/cmdc.202000643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
28 Olaoye OO, Watson PR, Nawar N, Geletu M, Sedighi A, Bukhari S, Raouf YS, Manaswiyoungkul P, Erdogan F, Abdeldayem A, Cabral AD, Hassan MM, Toutah K, Shouksmith AE, Gawel JM, Israelian J, Radu TB, Kachhiyapatel N, de Araujo ED, Christianson DW, Gunning PT. Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype. J Med Chem 2021;64:2691-704. [PMID: 33576627 DOI: 10.1021/acs.jmedchem.0c01922] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]